Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103553 | 0.91 | CNR1 (0.58) | CNR1IDH1PKMKMT2A | |
| SCHEMBL3104836 | 0.90 | CNR1 (0.56) | CNR1CNR2IDH1KMT2A | |
| SCHEMBL3224422 | 0.90 | CNR1 (0.52) | CNR1CNR2IDH1KMT2A | |
| SCHEMBL3114375 | 0.88 | CNR1 (0.58) | CNR1IDH1PKMRAB9AKMT2A | |
| SCHEMBL3110050 | 0.86 | CNR1 (0.60) | CNR1CNR2IDH1KMT2A | |
| SCHEMBL3713619 | 0.81 | CNR1 (0.53) | CNR1CNR2KMT2A | |
| SCHEMBL4912775 | 0.80 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL4913349 | 0.78 | TRPV1 (0.52) | MAPK1 | |
| SCHEMBL3114608 | 0.77 | DPP4 (0.44) | — | |
| SCHEMBL3107244 | 0.76 | PPARD (0.44) | CNR1CNR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362045-B2 | 5,6-diaryl pyridines substituted in the 2- and 3-position, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256202-A1 | 5,6-DIARYL PYRIDINES SUBSTITUTED IN THE 2- AND 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ALK, ROS1, CYP11B2 | CNR1 11/4885CNR2 4/4885KLKB1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.